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1. Abstract: 
Multimorbidities are associated with significant burden on the healthcare system and the lack of accurate and 
pertinent statistical exploratory techniques have often limited their analysis. Here we employ exploratory 
hierarchal agglomerative clustering (HAC) of multimorbidities in the inpatient population in the state of Ohio. 
The examination exposed the presence of ten discrete, clinically pertinent groups of multimorbidities within 
the Ohio inpatient population. This method offers an assessable empirical exploration of the multimorbidities 
present in a specific geographic populace. 
2. Introduction: 
Patients with more than one chronic conditions are referred to as multimorbid patients. The incidence of such 
multimorbid patients has increased due to the rise in the aging population in the US leading to significant 
impact on the overall health care outcomes. Numerous mechanisms may lie beneath these multimorbidities, 
including direct relationship, associated risk features, heterogeneity, and individual differences 1,2. There has 
been an augmented acknowledgment of its bearing and the significance of improving consequences for such 
multimorbid patients3–5. The lack of proper and statistical exploratory techniques have often limited the 
analysis of such chronic multimorbidities.   
Clustering, is an unsupervised data mining algorithm that groups similar units into similar clusters, thus 
partitioning dissimilar objects into other clusters6–10. Hierarchical agglomerative clustering is a repeated 
subdivision of a dataset into clusters at an progressively finer granularity11. HAC has previously been 
employed to find clusters in microarray data12, employed in nursing research10, and to find molecular genetic 
markers9.  In the current study, we use unsupervised clustering exploration to discover the cohorts of cohorts 
present in the Ohio patient population. The described clustering method classifies units of multi-morbidities 
and presents prospects for improved supervision of multimorbid patients. 
3. Methods: 
3.1 Study Population 
We used open access de-identified aggregate data provided by the Ohio Department of State Health 
Services for this research. Several exclusions including pregnant females, cancer, patients in hospice or long 
term care were excluded from the analysis. Further, patients only within the ages of 40 to 80 were identified 
for this multimorbidity analysis. Identification of conditions within unit associates were founded on an 
in/outpatient data matched to International Classification of Diseases, Tenth Revision (ICD-10) diagnosis 
codes in 201513 
3.2 Exploratory Data Analysis and Feature Generation 
Apache Hadoop database was used to store, query and extract the dataset extracted from the online 
resource. One step hot encoding was used for dichotomous target features for selected disorders. 
Demographic variables were appended to the data set to enable broader interpretation. Data missing at 
random was imputed by median/mode for continuous/categorical features.  
3.3 Statistical Analysis 
The R suite of statistical programs was used for quantitative analysis (Version 0.9). Statistical procedures 
used are described previously in other studies 6,14–16,16–20.  
3.4 Clustering Algorithm 
An agglomerative hierarchical clustering (AHC) algorithm with a bottom up approach was used to separate 
clinically appropriate clusters within the study population. The bottom up aproach to AHC initiates with each 
member starting at an isolated cluster, followed by serial merging of similar members to form similarity 
clusters until only once cluster remains. After the clustering procedure terminates, subject matter expertise, 
clinical relevance and study design criterion are used to select a cutoff/threshold which produces the final 
clusters. The process can be visualized using dendrograms. We used Ward’s method along with Gower’s 
distance matrix for similarity calculations as it has shown to be more reliable for mixed data with a 
preponderance of weighted binary data (like condition related binary variables)21.  
4. Results: 
4.1 Clustering Analysis reveals ten broad cluster of multi-morbidity patients in the population 
Agglomerative Hierarchal Clustering revealed 10 broad clusters in the population data of 14,444 patients 
(Figure 1). The average age of patients was 73.0 years and contained 48.7 % males and 58.3 % females.  
 
Figure 1: Results from hierarchical agglomerative clustering reveal nine distinct clusters. Clustering was 
performed using Ward’s method with Gower’s distance and a threshold (h=27; shown as a dotted line) 
was used to isolate 10 clusters. 
Descriptive statistics revealed clinical homogeneity within the clusters (Table 1). The clusters (numbered 
randomly) were divergent based on the mix of multimorbidities observed and age/gender demographics.  
Clinically relevant summarization showed the presence of distinct clusters with a high proportion of patients 
with (Table 2) : metabolic syndromes (cluster 1), cancer (cluster 2), gastro related diseases (cluster 3), 
hypertensive patients (cluster 4), stomach cancer and related conditions (cluster 5), heart failure and COPD 
(cluster 6), Obesity related morbidities like lower back pain (cluster 7), Epilepsy (cluster 8), osteoarthritis 
(cluster 9) and old age related disorders like Parkinson’s (cluster 10). Income, medical utilization, inpatient 
visits were also calculated but are not shown in the current analysis due to HIPPA restrictions. 
Cluster # 1 2 3 4 5 6 7 8 9 10 
size 1193 2319 1600 2108 1139 1494 1212 2065 807 507 
age (mean) 68.5 62.2 75.7 76.4 77 72.9 69.9 77.5 79.2 81.1 
males (%) 42.5 45.2 57.7 48.8 40.9 56.5 32.6 59.3 48.9 43 
females (%) 57.5 54.8 42.3 51.2 59.1 43.5 67.4 40.7 51.1 57 
Hospital Visits (mean) 0.73 0.94 1.14 0.98 0.68 0.89 0.94 0.91 0.82 1.07 
Diabetes Mellitus (%) 0 0.2 0.2 0.1 0.2 0.2 0.2 0 0 0.2 
Heart Failure (%) 0.4 0.4 0.4 0.4 0.2 0.7 0.2 0.2 0.5 0.2 
COPD (%) 0.2 0.6 0.3 0.4 0.5 1.5 0.1 0.2 0.4 0.2 
Ischemic Heart 
Disease (%) 
0 0.2 0 0 0.1 0.4 0 0.1 0 0 
Otitis Media (%) 63.4 16.4 83 75.7 30.5 67.9 49.6 28.2 29.5 44.4 
Peptic Ulcer Disease 
(%) 
19.4 4.7 81.9 71.5 13.3 34.1 44.6 53.9 49.4 50.3 
Hypertension (%) 32.7 23.8 35.4 67.3 25.1 23 66.5 46.9 47.8 45.6 
Epilepsy (%) 22 6.7 77.6 67.1 28.4 14.3 57.9 78.3 33.2 62.7 
Chronic Thyroid 
Disorders (%) 
1.3 1 1 1.5 1.1 0.5 2.9 1.2 0.7 1.2 
Depression (%) 3.1 2.8 2.4 6.3 2.5 1.9 4.7 2.9 3.5 4.5 
Cholelithiasis 
Cholecystitis (%) 
95.3 51.5 99 98.3 93.4 88 93 95.7 93.9 97 
Iron Deficiency 
Anemia (%) 
1.8 7.7 4.6 3.8 1.2 3.3 7.3 5 5.1 11.8 
Osteoarthritis (%) 31.3 17.4 24.9 34.3 28.4 24.2 33.9 26.1 37.2 25.6 
Rheumatoid Arthritis 
(%) 
23.7 32.9 20.9 38.5 24.5 13.4 70.1 17.5 18.3 71 
Colorectal Cancer (%) 2.6 2.5 2.9 4.4 1.8 2.3 3.1 2.3 2.9 3.4 
Lung Cancer (%) 10.7 6.3 23.1 15.8 12.2 10.8 11.5 9.2 16 15.2 
Hyperlipidemia (%) 60.9 17.9 27.9 49.8 89.5 14 61.6 24.3 42.5 42.2 
Cerebrovascular 
Disease (%) 
4.9 2.5 2.6 5.6 9 2.4 13.7 2.4 4.8 3.9 
Headaches Migrane 
Othrs (%) 
1.4 4.4 3.3 3.6 3.7 3.1 1.3 2.5 5 2.4 
Chronic Renal Failure 
(%) 
0.8 3.8 1.8 2.6 1.6 2.2 3.2 5.2 3.8 2.2 
Kidney Stones (%) 77.9 44.8 91.2 92.4 72.5 69.5 84.4 84.3 79.3 88.8 
Diverticular Disease 
(%) 
14.6 11.1 33.4 35.1 11.4 14.9 26.3 46.4 36.6 64.5 
Low Back Pain (%) 7.7 15 4.8 8.2 4.5 4.2 28 7.1 6.8 18.1 
Nonspec Gastr 
Dyspepsia (%) 
32.1 7.5 79.3 78.9 23.4 35.4 18.2 29.9 36.4 49.5 
Sickle Cell Anemia 
(%) 
3.3 4 4.8 7 4.7 3.7 6.3 3.5 5.2 3.2 
Multiple Sclerosis (%) 6.1 4.6 4.4 13.4 11.4 2.2 11.8 5.5 12.5 11.2 
Inflammatory Bowel 
Disease (%) 
56.4 39.5 22.5 60.8 48.3 14.3 72.5 39.4 40.3 44.2 
Hemo Congntl 
Coagulopathies (%) 
63.4 44.2 50.4 68.6 54.4 31.9 75.5 50.8 52.8 76.1 
Systemic Lupus Ery 
(%) 
0.2 0.6 0.3 0.8 0 0.1 0.2 0 0.4 0.2 
Prostate Cancer (%) 0.2 1.1 0.2 0.5 0.4 0.4 0.9 0.3 0.4 0.2 
Ovarian Cancer (%) 2.3 5.1 0.5 1.2 1.5 1.4 2.8 1.4 2 1.4 
Endometrial Cancer 
(%) 
1.4 1.1 0.2 1.2 0.4 0.6 3.3 0.6 0.4 0.8 
Cervical Cancer (%) 5.1 2.1 7.7 7.5 6 5.8 2 7 8.6 9.5 
Hodgkin Dis 
Lymphoma (%) 
0.1 1 0.1 0.3 0.4 0.1 0 0.2 0.5 0.2 
Leukemia Myeloma 
(%) 
0.3 0.9 0.2 0.5 0.3 0.5 0.7 0.2 0.5 0.2 
Malignant Melanoma 
(%) 
0.2 0.5 0 0.2 0.3 0.1 0.1 0 0.1 0.2 
Head Neck Cancer 
(%) 
1.1 3 1.4 1.2 1.5 1.7 1.9 1.7 1.4 1.4 
Esophageal Cancer 
(%) 
1.3 2.5 2.4 2.3 1.8 3.4 0.8 1.8 3.5 1.6 
Stomach Cancer (%) 1.3 1.1 1.3 1 3.8 1 1.3 3.1 2 1 
Pancreatic Cancer 
(%) 
0.3 2.1 0.4 0.6 1.1 0.4 0.3 1.2 0.4 0.2 
Pancreatitis (%) 0.2 0.6 0.1 0.1 0 0.5 0.2 0.3 0.6 0.2 
Hepatitis (%) 2.5 6.9 2 4.7 1.8 1.5 3.6 1.4 2.5 2.8 
Peripheral Artery 
Disease (%) 
2.8 5.5 1.8 1.9 2.2 4.5 4.3 1.7 1.6 2.2 
Endometriosis (%) 15.5 8.3 40.9 86 24.1 12.4 44.8 38.9 41.6 60.2 
Ventricular Arrhythmia 
(%) 
0.1 0.5 0 0 0 0 0.2 0 0 0 
Lyme Disease (%) 2.2 1.5 12.2 8.3 2.2 3.1 5.9 10.4 5.3 3.7 
Female Infertility (%) 0 0.1 0.1 0 0.2 0.1 0.2 0 0.1 0 
Menopause (%) 0.1 0.1 0 0 0 0 0 0 0 0 
Glaucoma (%) 3.7 2.8 1.5 3.7 4.7 1.7 10.1 2.7 3.5 4.1 
Low Vision Blindness 
(%) 
9.3 3.8 17.6 22.2 9.2 10.9 14.4 10.7 52.3 31.2 
Cataract (%) 0.6 0.6 1.7 1.5 1.3 0.9 0.9 0.5 0.4 3.2 
Other Cancer (%) 11.7 5.2 13.9 43.1 13.9 11.1 24.1 13.3 64.6 30.4 
Dementia (%) 3.2 11.2 4.4 6.4 7.1 10.1 4.5 7.2 7.4 4.3 
Osteoporosis (%) 5.5 4.7 9.5 11.5 8.6 16.9 10.6 8.2 10.7 86.8 
Obesity (%) 7.3 6.6 7 16 20.8 2.9 24.8 7.1 9 21.3 
Oral Cancer (%) 87.1 11 43.7 59.3 11.8 17.3 62.4 18.1 20.3 21.3 
Cystic Fibrosis (%) 0 1.7 0.4 0.5 0.6 0.2 0.3 0.6 0.2 0.2 
Neurosis (%) 0.2 0.3 0 0 0 0 0.2 0.1 0 0 
Psychoses (%) 1.3 5.5 1.9 1.8 1.1 1.3 6.7 1.7 1.5 8.3 
Eating Disorders (%) 0 0.2 0.1 0.1 0 0 0.2 0 0 0.6 
Disrupt Childhd 
Disorders (%) 
0.2 0.1 0.1 0 0 0 0.2 0 0 0.2 
Substance Reltd 
Disorders (%) 
7 19.6 4.4 22 5.4 2.9 28.1 5.3 3.8 7.9 
Skin Cancer (%) 4.9 3.8 5.8 5.8 19.5 5.6 7 21.4 11 9.1 
Congenital Heart 
Disease (%) 
0.8 0.4 1.5 1.6 0.4 0.5 0.9 1.1 1.5 1.4 
Periodontal Disease 
(%) 
0.8 0.7 0.6 0.4 1.1 0.7 0.4 0.4 0.4 0.6 
Chronic Fatigue 
Syndrome (%) 
0.6 0.6 0.6 0.9 0.4 0.2 1.6 1.1 0.6 0.6 
Fibromyalgia (%) 3.9 3.8 1.2 2.7 3.1 0.7 14.9 1.2 2.2 2 
Parkinson Disease 
(%) 
1.3 0.9 1.6 2.8 2.3 2.7 2.1 1.9 1.7 15.4 
Hypercoaguable 
Syndome (%) 
1 1.1 0.8 1.2 1.3 1.2 1.7 0.9 1.4 1.4 
Post Partum BH 
Disorder (%) 
0 0.2 0 0 0 0 0 0 0 0 
Metabolic Syndrome 
(%) 
23.3 6.8 3.3 3.2 3.6 2.5 7 5.7 4.8 4.3 
Psyc Dis rltd Med 
Condtns (%) 
1.5 2.9 1.5 2.2 1.6 2 4.3 1.3 2.9 23.1 
Table 1: Summaries of disease distributions in different clusters. This table shows cluster summaries for age (median; years), male 
and female composition (%), and the proportion of people identified with different medical conditions (%; number members in 
cluster with the disease/ total number of members with the disease), for the nine clusters. 
5. Discussion: 
In the present study we use the HAC approach to categorize clusters of patient with analogous 
multimorbidities in the Ohio population. The clusters identified were consistent and clinically applicable with 
relevant insights. We describe a rapid, data driven, scalable method to discover multimorbidity cohorts in the 
patient data. HAC on the Ohio patient health data to isolate multimorbidity patients revealed ten well defined 
clusters. An analysis of the most prevalent conditions in every cluster revealed broad groupings within each 
cluster (Table 2).  
Our first cluster had 1,193 patients. It contained middle aged patients (median age 68.5 years) and had a 
slightly higher ratio of females (58%) compared to females (42%). The cluster was characterized by the 
highest incidence of oral cancer (87%) and metabolic syndrome (23%). Indeed, a 2015 meta-analysis 
revealed an association between metabolic syndrome and oral cancer22. Our second cluster had a higher 
ratio of younger females (55% females with median age of 62.2 years) and had the highest incidences of 
conditions like ovarian cancer (5.1%), cystic fibrosis (1.7%), pancreatic cancer (2.1%), hepatitis (6.9%) and 
post-partum birth disorders (0.2%). This was also our youngest cluster. Recent research has shown a linkage 
between ovarian cancers, pancreatic cancer and post-partum disorders further strengthening these causal 
findings23–25. 
Cluster  Summary 
1 Metabolic Syndrome group 
2 Cancer group 
3 Peptic Ulcer group 
4 Kidney Stones group 
5 Hyperlipidemia and stomach cancer group 
6 Heart Failure and Ischemic Heart Disease group 
7 Obesity related conditions group 
8 Epilepsy group 
9 Osteoarthritis group 
10 Osteoporosis group 
Table 2:  A summary of clinical findings from each cluster. 
Cluster three was an older cluster (median age 75.7 years), with more males compared to females (58% 
males). This cluster contained the highest percentage of members with stomach conditions including peptic 
ulcers (82%), cholecystitis (99%), non-specific gastric dyspepsia (79%). Interestingly, we also found the 
highest incidence of lung cancer (23%) in this patient cohort. This association has previously been attributed 
to metastasis26. 
Cluster 4 was gender equal and contained a high proportion of older patients with (median age 76.4 years; 
51 % females; 49% male) with 92% of the members with kidney stones. Other conditions also seen in this 
cluster included colorectal cancer (4%), hypertension (67%), multiple sclerosis (13%) and congenital heart 
disease (2%). Alexander and colleagues, in a retrospective study have previously shown the how chronic 
hypertension is strongly linked and indicative of calcium oxalate crystal formation hinting at the root cause of 
this association27. Cluster 5, contained 1139 patients and a very high proportion of patients with 
hyperlipidemia (90%) and stomach cancer (4%). Recent research has shown significant association between 
the two conditions28,29. 
Cluster 6 contained 1,494 patients, was more male skewed (57%), with a median age of 72.9 years. This 
cluster was predominantly dominated by heart diseases like heat failure (0.7%) and ischemic heart disease 
(0.4%). 
Cluster 7 also had a high proportion of young females (67% females; median age 69.9 years) who reported 
a myriad of related disorders including chronic thyroid conditions (2.9%), endometrial cancer (3.3%), female 
infertility (0.2%), disrupted childhood disorder (0.2%) and obesity (24.8%). Similar multi-morbidity 
associations have extensively been studied in these patientis30–32.  
Cluster 8, was one of the older clusters (median age 77.5 years) with the highest proportion of males (59.3% 
males) with a majority of the members with epilepsy (78%). Epilepsy, one of the most prevalent neurological 
conditions with no known cure, is frequently seen in this subgroup33,34.  Cluster 9 had more females (52%) 
with a median age of 79.2 years with a high proportion of patients with osteoarthritis (37%) and low vision 
blindness (52%). Cluster 10, our smallest cluster with only 507 members, was also our oldest with a median 
age of 81.1 years and a higher proportion of females (57%). This cluster consisted of diseases like 
osteoporosis (87%) and, rheumatoid arthritis (71%) and diverticular disease (64%). Osteoporosis and 
rheumatoid arthritis have often been linked to have similar mechanisms linked to interleukin-6 dysfunction 35–
37 and this association further strengthens this hypothesis. This study has identified clinically relevant 
multimorbid clusters in a general population and can thus be used to profile patients in other geographies.
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